The PD-L1/B7.1 and PD-L1/PD-1 pathways can protect tumors from cytotoxic T cells, ultimately inhibiting the antitumor immune response in two ways:

• Deactivating cytotoxic T cells in the tumor microenvironment
• Preventing priming and activation of new T cells in the lymph nodes and subsequent recruitment to the tumor

PD-L1 binds to T cell receptors B7.1 and PD-1, deactivating cytotoxic T cells. Once deactivated, T cells remain inhibited in the tumor microenvironment.

Why PD-1?

• PD-1 and PD-L1 are important checkpoints in tumor development
• PD-1/PD-L1 pathway is a promising target for treating NSCLC
• Receptor expressed primarily on activated T cells
• Aid to identify disease types to treatment

Immunohistochimie sur coupes de paraffine fixées au formalin de tissu pulmonaire humain avec un carcinome cellulaire squameux.	Clone	DBM15.1
	Isotype	IgG murin
	Espèce cible	Humain
	Application	IHC
	Localisation Cellulaire	Membrane

 

---

Products	Volume	Format	Cat#
Mouse Anti-PD-1 Antibody	0,5 ml	Concentrated	MOB475-05
	1 ml		MOB475-1
	6 ml	Ready-to-use	PDM190-6
	25 ml		PDM190-25